{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:05:43Z","timestamp":1773288343539,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"vor","delay-in-days":5374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1093\/annonc\/mdi125","type":"journal-article","created":{"date-parts":[[2005,3,2]],"date-time":"2005-03-02T03:38:07Z","timestamp":1109734687000},"page":"634-639","source":"Crossref","is-referenced-by-count":42,"title":["Interferon-\u03b1 as maintenance therapy in patients with multiple myeloma"],"prefix":"10.1016","volume":"16","author":[{"given":"C.G.","family":"Schaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"te Marvelde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"le Cessie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.P.","family":"Breed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.E.","family":"Fibbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.A.","family":"van Deijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Fickers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.J.","family":"Roozendaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.","family":"Wijermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdi125_bb0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi125_bb0015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","article-title":"The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients","volume":"113","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi125_bb0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-\u03b1 treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi125_bb0025","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi125_bb0030","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/bjc.1990.434","article-title":"Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist","volume":"62","author":"de Haes","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdi125_bb0035","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdi125_bb0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7326\/0003-4819-124-2-199601150-00004","article-title":"The Nordic Myeloma Study Group. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial","volume":"124","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdi125_bb0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/oxfordjournals.annonc.a059217","article-title":"Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies","volume":"6","author":"Ludwig","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi125_bb0050","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1200\/JCO.1998.16.8.2834","article-title":"Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma","volume":"16","author":"Zee","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi125_bb0055","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma","volume":"92","author":"Wisloff","year":"1996","journal-title":"Nordic Myeloma Study Group. Br J Haematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419477478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419477478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/16\/4\/634\/416005\/mdi125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T10:04:45Z","timestamp":1735121085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419477478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0923753419477478"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdi125","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}